Cancer immunotherapy

Volume: 31 Number: 4 August 1, 2015
  • Mustafa Burak Barbaros
  • Miriş Dikmen
EN TR

Cancer immunotherapy

Abstract

As one of the spesific methods in cancer treatment, immunotherapy means to treat some diseases such as canncer by using one’s particular parts of immune system. Due to its ability to prevent damage to healthy cells by directly targeting cancer cells, it attracts more attention everyday. In immunotherapy, it’s possible to create immune response by stimulating body’s own cells or with externally supplied substances. From the second half of the 19th century till today, various immunotherapy methods found themselves a place in practice. Through better understandng of the mechanisms of development, prevention and elimination of cancer, advances in all immunotherapeutic methods also take place. Today, monoclonal antbodies, adoptive immunotherapy, vaccines, cytokines and immune system supporting treatmens are developed and applied aganist cancer in this context. In the light of current literature, this study reviews information about cancer immunotherapy.

Keywords

References

  1. American Cancer Societya, Cancer Immunotherapy, Copyright tarihi:24.05.2015 Cancer Society. Erişim
  2. Zhou J., Advances and Prospects in Cancer Immunotherapy, New Journal of Science, 2014, 1-13, 2014.
  3. Wayteck L., Breckpot K., Demeester J., De Smedt S. C., Raemdonck K., A Personalized View on Cancer Immunotherapy, Cancer Letters, 352(2014), 113-125, 2013.
  4. Aslan G., Tümör İmmünolojisi, Turk. J. Immunol., 15(1), 7- 13, 2010.
  5. Curiel T. J., Cancer Immunotherapy: Paradigms, Practice and Promise, s. 5, Springer Science+Business Media, New York, 2013.
  6. Eskander R. M., Tewari K. S., Immunotherapy: An Evolving Paradigm in the Treatment of Advanced Cervical Cancer, Clinical Therapeutics, 37(1), 20-38, 2015.
  7. Parish C. R., Cancer Immunotherapy: The Past, the Present and the Future, Immunology and Cell Biology, 81, 106-113, 2003.
  8. Waldmann T., Immunotherapy: Past, Present and Future, Nature Medicine, 9(3), 269-277, 2003.

Details

Primary Language

English

Subjects

-

Journal Section

-

Authors

Mustafa Burak Barbaros This is me

Miriş Dikmen This is me
Anadolu Üniversitesi, Eczacılık Fakültesi, Farmakoloji Anabilim Dalı, Eskişehir, Türkiye

Publication Date

August 1, 2015

Submission Date

August 1, 2015

Acceptance Date

-

Published in Issue

Year 2015 Volume: 31 Number: 4

APA
Barbaros, M. B., & Dikmen, M. (2015). Cancer immunotherapy. Erciyes Üniversitesi Fen Bilimleri Enstitüsü Fen Bilimleri Dergisi, 31(4), 177-182. https://izlik.org/JA38RW77FT
AMA
1.Barbaros MB, Dikmen M. Cancer immunotherapy. Erciyes Üniversitesi Fen Bilimleri Enstitüsü Fen Bilimleri Dergisi. 2015;31(4):177-182. https://izlik.org/JA38RW77FT
Chicago
Barbaros, Mustafa Burak, and Miriş Dikmen. 2015. “Cancer Immunotherapy”. Erciyes Üniversitesi Fen Bilimleri Enstitüsü Fen Bilimleri Dergisi 31 (4): 177-82. https://izlik.org/JA38RW77FT.
EndNote
Barbaros MB, Dikmen M (August 1, 2015) Cancer immunotherapy. Erciyes Üniversitesi Fen Bilimleri Enstitüsü Fen Bilimleri Dergisi 31 4 177–182.
IEEE
[1]M. B. Barbaros and M. Dikmen, “Cancer immunotherapy”, Erciyes Üniversitesi Fen Bilimleri Enstitüsü Fen Bilimleri Dergisi, vol. 31, no. 4, pp. 177–182, Aug. 2015, [Online]. Available: https://izlik.org/JA38RW77FT
ISNAD
Barbaros, Mustafa Burak - Dikmen, Miriş. “Cancer Immunotherapy”. Erciyes Üniversitesi Fen Bilimleri Enstitüsü Fen Bilimleri Dergisi 31/4 (August 1, 2015): 177-182. https://izlik.org/JA38RW77FT.
JAMA
1.Barbaros MB, Dikmen M. Cancer immunotherapy. Erciyes Üniversitesi Fen Bilimleri Enstitüsü Fen Bilimleri Dergisi. 2015;31:177–182.
MLA
Barbaros, Mustafa Burak, and Miriş Dikmen. “Cancer Immunotherapy”. Erciyes Üniversitesi Fen Bilimleri Enstitüsü Fen Bilimleri Dergisi, vol. 31, no. 4, Aug. 2015, pp. 177-82, https://izlik.org/JA38RW77FT.
Vancouver
1.Mustafa Burak Barbaros, Miriş Dikmen. Cancer immunotherapy. Erciyes Üniversitesi Fen Bilimleri Enstitüsü Fen Bilimleri Dergisi [Internet]. 2015 Aug. 1;31(4):177-82. Available from: https://izlik.org/JA38RW77FT

Ethics and Compliance Requirements

✯ For all studies that require ethics committee approval, such approval must be obtained, clearly stated within the manuscript, and properly documented.

✯ In research requiring ethics approval, detailed information—the name of the ethics committee, approval date, and approval number—must be included in the Methods section, and additionally on either the first or last page of the manuscript. For case reports, the manuscript must include a statement confirming that written informed consent was obtained from the participant(s).

✯ The journal’s website must include a clear statement confirming that all manuscripts comply with Research and Publication Ethics.

✯ Ethical responsibilities and guidelines for authors, reviewers, and editors must be presented under separate headings on the journal’s website.

✯ Ethical principles must be explicitly stated in the journal and/or on the journal website, with reference to national and international standards. For instance, scientific manuscripts submitted to the journal should follow the recommendations of the ICMJE (International Committee of Medical Journal Editors) and the COPE (Committee on Publication Ethics) International Standards for Editors and Authors.

✯ Compliance with relevant copyright regulations is mandatory for all intellectual and artistic works used within the manuscript.